346 related articles for article (PubMed ID: 19012178)
1. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease.
Heptinstall S; Espinosa DI; Manolopoulos P; Glenn JR; White AE; Johnson A; Dovlatova N; Fox SC; May JA; Hermann D; Magnusson O; Stefansson K; Hartman D; Gurney M
Platelets; 2008 Dec; 19(8):605-13. PubMed ID: 19012178
[TBL] [Abstract][Full Text] [Related]
2. PGE(2) reverses G(s)-mediated inhibition of platelet aggregation by interaction with EP3 receptors, but adds to non-G(s)-mediated inhibition of platelet aggregation by interaction with EP4 receptors.
Glenn JR; White AE; Iyu D; Heptinstall S
Platelets; 2012; 23(5):344-51. PubMed ID: 22436052
[TBL] [Abstract][Full Text] [Related]
3. Antagonists of the EP3 receptor for prostaglandin E2 are novel antiplatelet agents that do not prolong bleeding.
Singh J; Zeller W; Zhou N; Hategen G; Mishra R; Polozov A; Yu P; Onua E; Zhang J; Zembower D; Kiselyov A; Ramírez JL; Sigthorsson G; Bjornsson JM; Thorsteinsdottir M; Andrésson T; Bjarnadottir M; Magnusson O; Fabre JE; Stefansson K; Gurney ME
ACS Chem Biol; 2009 Feb; 4(2):115-26. PubMed ID: 19193156
[TBL] [Abstract][Full Text] [Related]
4. P2Y₁₂ and EP3 antagonists promote the inhibitory effects of natural modulators of platelet aggregation that act via cAMP.
Iyú D; Glenn JR; White AE; Fox SC; Dovlatova N; Heptinstall S
Platelets; 2011; 22(7):504-15. PubMed ID: 21591981
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors.
Petrucci G; De Cristofaro R; Rutella S; Ranelletti FO; Pocaterra D; Lancellotti S; Habib A; Patrono C; Rocca B
J Pharmacol Exp Ther; 2011 Feb; 336(2):391-402. PubMed ID: 21059804
[TBL] [Abstract][Full Text] [Related]
6. Detection of P2Y(14) protein in platelets and investigation of the role of P2Y(14) in platelet function in comparison with the EP(3) receptor.
Dovlatova N; Wijeyeratne YD; Fox SC; Manolopoulos P; Johnson AJ; White AE; Latif ML; Ralevic V; Heptinstall S
Thromb Haemost; 2008 Aug; 100(2):261-70. PubMed ID: 18690346
[TBL] [Abstract][Full Text] [Related]
7. PGE1 and PGE2 modify platelet function through different prostanoid receptors.
Iyú D; Jüttner M; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
Prostaglandins Other Lipid Mediat; 2011 Feb; 94(1-2):9-16. PubMed ID: 21095237
[TBL] [Abstract][Full Text] [Related]
8. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques.
Penz SM; Reininger AJ; Toth O; Deckmyn H; Brandl R; Siess W
Thromb Haemost; 2007 Mar; 97(3):435-43. PubMed ID: 17334511
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding.
Singh J; Zeller W; Zhou N; Hategan G; Mishra RK; Polozov A; Yu P; Onua E; Zhang J; Ramírez JL; Sigthorsson G; Thorsteinnsdottir M; Kiselyov AS; Zembower DE; Andrésson T; Gurney ME
J Med Chem; 2010 Jan; 53(1):18-36. PubMed ID: 19957930
[TBL] [Abstract][Full Text] [Related]
10. Effects on platelet function of an EP3 receptor antagonist used alone and in combination with a P2Y12 antagonist both in-vitro and ex-vivo in human volunteers.
Fox SC; May JA; Johnson A; Hermann D; Strieter D; Hartman D; Heptinstall S
Platelets; 2013; 24(5):392-400. PubMed ID: 22866894
[TBL] [Abstract][Full Text] [Related]
11. Agonist concentration-dependent differential responsivity of a human platelet purinergic receptor: pharmacological and kinetic studies of aggregation, deaggregation and shape change responses mediated by the purinergic P2Y1 receptor in vitro.
Maayani S; Schwarz TE; Patel ND; Craddock-Royal BD; Tagliente TM
Platelets; 2003; 14(7-8):445-62. PubMed ID: 14713514
[TBL] [Abstract][Full Text] [Related]
12. Acyl derivatives of coenzyme A inhibit platelet function via antagonism at P2Y1 and P2Y12 receptors: a new finding that may influence the design of anti-thrombotic agents.
Manolopoulos P; Glenn JR; Fox SC; May JA; Dovlatova NL; Tang SW; Thomas NR; Ralevic V; Heptinstall S
Platelets; 2008 Mar; 19(2):134-45. PubMed ID: 18297551
[TBL] [Abstract][Full Text] [Related]
13. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence.
Tilly P; Charles AL; Ludwig S; Slimani F; Gross S; Meilhac O; Geny B; Stefansson K; Gurney ME; Fabre JE
Cardiovasc Res; 2014 Mar; 101(3):482-91. PubMed ID: 24323317
[TBL] [Abstract][Full Text] [Related]
14. The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function.
Iyú D; Glenn JR; White AE; Johnson AJ; Fox SC; Heptinstall S
Platelets; 2010; 21(5):329-42. PubMed ID: 20433310
[TBL] [Abstract][Full Text] [Related]
15. Mode of action of P2Y(12 ) antagonists as inhibitors of platelet function.
Iyú D; Glenn JR; White AE; Fox SC; van Giezen H; Nylander S; Heptinstall S
Thromb Haemost; 2011 Jan; 105(1):96-106. PubMed ID: 20941457
[TBL] [Abstract][Full Text] [Related]
16. The active metabolite of prasugrel effectively blocks the platelet P2Y12 receptor and inhibits procoagulant and pro-inflammatory platelet responses.
Judge HM; Buckland RJ; Sugidachi A; Jakubowski JA; Storey RF
Platelets; 2008 Mar; 19(2):125-33. PubMed ID: 18297550
[TBL] [Abstract][Full Text] [Related]
17. Effects of P2Y(1) and P2Y(12) receptor antagonists on platelet aggregation induced by different agonists in human whole blood.
Storey RF; Newby LJ; Heptinstall S
Platelets; 2001 Nov; 12(7):443-7. PubMed ID: 11674863
[TBL] [Abstract][Full Text] [Related]
18. Potentiation of platelet aggregation by heparin in human whole blood is attenuated by P2Y12 and P2Y1 antagonists but not aspirin.
Storey RF; May JA; Heptinstall S
Thromb Res; 2005; 115(4):301-7. PubMed ID: 15668190
[TBL] [Abstract][Full Text] [Related]
19. Augmentation of U46619 induced human platelet aggregation by aspirin.
Kim JM; Koo YK; Jin J; Lee YY; Park S; Yun-Choi HS
Platelets; 2009 Mar; 20(2):111-9. PubMed ID: 19235053
[TBL] [Abstract][Full Text] [Related]
20. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
